HC Wainwright Brokers Reduce Earnings Estimates for MLTX

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of MoonLake Immunotherapeutics in a note issued to investors on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.70) per share for the quarter, down from their prior forecast of ($0.62). HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.34) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q4 2026 earnings at ($0.69) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.72) EPS, Q3 2027 earnings at ($0.76) EPS and FY2027 earnings at ($2.67) EPS.

Other research analysts also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Friday, August 7th. Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. BTIG Research restated a “buy” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th. Finally, Leerink Partners lifted their target price on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics presently has an average rating of “Hold” and an average target price of $24.57.

MoonLake Immunotherapeutics Stock Down 0.1%

MoonLake Immunotherapeutics stock opened at $16.34 on Monday. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -4.26 and a beta of 1.06. The stock’s fifty day moving average is $18.84 and its two-hundred day moving average is $17.91. The company has a debt-to-equity ratio of 0.23, a quick ratio of 12.56 and a current ratio of 12.56.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.07.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 50,000 shares of the company’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $20.02, for a total value of $1,001,000.00. Following the transaction, the insider directly owned 2,714,746 shares in the company, valued at approximately $54,349,214.92. This represents a 1.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the sale, the chief executive officer directly owned 2,774,893 shares in the company, valued at $55,553,357.86. This represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 344,800 shares of company stock worth $6,820,071. Corporate insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of institutional investors have recently modified their holdings of MLTX. Kestra Advisory Services LLC acquired a new stake in MoonLake Immunotherapeutics during the fourth quarter worth approximately $26,000. EverSource Wealth Advisors LLC grew its stake in MoonLake Immunotherapeutics by 221.1% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock worth $53,000 after acquiring an additional 1,974 shares during the period. FNY Investment Advisers LLC acquired a new position in MoonLake Immunotherapeutics in the 2nd quarter valued at $58,000. Russell Investments Group Ltd. raised its holdings in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after acquiring an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of MoonLake Immunotherapeutics during the 4th quarter worth $47,000. Institutional investors and hedge funds own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.